<DOC>
	<DOC>NCT00129623</DOC>
	<brief_summary>This 2 arm study will evaluate the efficacy and safety of oral Bonviva 150mg once monthly compared with placebo in post-menopausal women with osteopenia. Patients will be randomized to receive either Bonviva 150mg po monthly, or placebo monthly. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>women 4560 years of age; postmenopausal; ambulatory. vertebral fracture (except traumatic fracture such as in a motor vehicle accident); lowtrauma osteoporotic fracture in any other bone; breast cancer diagnosed within last 20 years; other malignancy diagnosed within last 10 years, except successfully resected basal cell cancer; treatment with any bisphosphonate within last 2 years; treatment with other drugs affecting bone metabolism within last 6 months.</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>